SCHEDULE 13G/A: BlackRock Amends Stake in Wave Life Sciences, Reports 6.1% Passive Ownership
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.1% beneficial ownership stake in Wave Life Sciences Ltd. as of December 31, 2024.
Summary
- BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in WAVE LIFE SCIENCES LTD.
- As of December 31, 2024, BlackRock, Inc. beneficially owns an aggregate of 9,360,163 shares of Common Stock of WAVE LIFE SCIENCES LTD.
- This ownership represents 6.1% of the total outstanding class of securities.
- BlackRock, Inc. holds sole voting power over 9,209,438 shares and sole dispositive power over 9,360,163 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Various business units, subsidiaries, and affiliates of BlackRock, Inc. contribute to this beneficial ownership, with some individual entities owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: Neutral. This is a routine regulatory filing disclosing beneficial ownership by a large institutional investor. It does not contain information that would inherently be positive or negative for the company's performance or outlook.
Future Outlook
N/A. This filing is a Schedule 13G, which reports beneficial ownership and does not typically include forward-looking statements or guidance from the issuer.
Industry Context
This Schedule 13G filing reflects a passive investment by BlackRock, a major global asset manager, in Wave Life Sciences Ltd., a biotechnology company. Such filings are standard disclosures for institutional investors holding significant stakes in publicly traded companies, indicating their position without implying active management or strategic influence over the issuer's operations.
Comparison to Industry Standards
- N/A. This document is a beneficial ownership report by an institutional investor and does not contain performance metrics or operational results that can be compared to industry standards or specific comparable companies/projects.
Stakeholder Impact
- This filing primarily impacts shareholders by providing transparency on significant institutional ownership.
- It confirms BlackRock's passive investment stance, which generally signals stability rather than an intent to influence corporate control.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Date of event requiring the filing of this statement. |
| 2025-01-21 | Date of execution of the Power of Attorney for BlackRock, Inc. |
| 2025-02-05 | Date of filing of the Schedule 13G Amendment No. 1. |
Keywords
BlackRock, Wave Life Sciences, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.